News

The ALK-inhibitor alectinib (Alecensa) was granted accelerated approval by the FDA for patients with metastatic non-small-cell lung cancer (NSCLC) whose disease progressed on crizotinib (Xalkori).

A new study has shown that overall quality of life is similar among patients taking tamoxifen or anastrozole, but patient reports on their hot flashes, night sweats, vaginal dryness, and joint pain can help illuminate which therapy may be right for a particular woman. And, the analysis shows, age matters.

The FDA has approved uridine triacetate (Vistogard) for the emergency treatment of adult and pediatric patients who had severe or life-threatening toxicities within 4 days of treatment following an overdose of 5-fluorouracil (5-FU) or capecitabine.

The immunotherapy agent avelumab yielded encouraging overall response rates (ORR) for patients with PD-L1–positive metastatic breast cancer and had an acceptable safety profile, according to findings reported at the San Antonio Breast Cancer Symposium (SABCS).

I will never forget the emotions – mostly disbelief and fear – that arose when I arrived at the cancer center.

Denosumab not only promotes bone health, it confers a survival advantage, according to data from a follow-up analysis of the ABCSG-18 trial reported at the 2015 San Antonio Breast Cancer Symposium (SABCS).

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

The FDA has cleared for marketing the nation’s first cooling cap—the Dignitana DigniCap Cooling System—to reduce the severity and frequency of hair loss in patients receiving chemotherapy for breast cancer.

Entering through the giant, inflatable colon, dozens of patients, caregivers, family members and providers gathered at the Georgetown University Hotel and Conference Center in Washington, DC, December 5 for the symposium, “Fighting a Smarter War Against Cancer.”

AARP study finds that caregivers provide much more than basic care.

Although patients with multiple myeloma and other plasma cell disorders (PCDs) are routinely vaccinated against influenza, studies show that a one-time flu shot does not confer an adequate immune response in these high-risk patients.

The kinase inhibitor Ibrutinib (Imbruvica) is a more effective frontline therapy than the traditional chemotherapy chlorambucil in treating older treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), reducing the risk of death by 84%.

African American women can reduce their risk of developing ovarian cancer by following healthy dietary guidelines, a recent study has found.

Disparities in colorectal cancer deaths have had a significant impact on the national economy, with areas of low socioeconomic status experiencing the greatest losses, according to a study by researchers at the Centers for Disease Control and Prevention (CDC).

Patients with breast cancer who have received anthracycline-based (ANTHR) chemotherapy may be more likely to experience "chemobrain"-a cancer-related cognitive impairment that can affect memory, attention, and physical function-than those treated with nonanthracycline-based regimens.

If you're facing a lung cancer diagnosis, it's not uncommon to feel afraid, confused, overwhelmed or just plain alone.

With the survival rate of childhood cancer improving and advancements in treatments allowing more of the care to take place in the home, the responsibility of caregiving is increasingly being placed on family members.

Linked to expansion of health insurance coverage.

The FDA has approved Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone for patients with multiple myeloma who have received one to three prior therapies.

This video features the compelling stories of EC survivors: Brian Galgay and Karen Kent.

As I looked at Ms C, I was struck by the pensive but engaged smile she always sent my way. The same look continued as her daughter elaborated on her mother's condition.

The FDA has approved nivolumab (Opdivo) as a frontline treatment for patients with BRAF wild-type advanced melanoma, based on a substantial improvement in overall survival (OS) compared with dacarbazine in a phase III study.

The combination of Portrazza (necitumumab) with gemcitabine and cisplatin has been FDA approved as first-line therapy for patients with locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). The approval is based on findings from the phase III SQUIRE trial.

In 2007, Zoila Pasos found a lump in her breast when she was just a few weeks pregnant. Not long into the pregnancy, she miscarried. While she allowed her body time to heal, she had the lump checked and was told it was a benign cyst and nothing to worry about.

Based on an extension in overall survival (OS) in the CheckMate-025 trial, Opdivo (nivolumab) has been approved by the FDA for patients with metastatic renal cell carcinoma (RCC) following prior treatment with an anti-angiogenic therapy.

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) has been fully approved by the FDA to treat patients with unresectable or metastatic BRAF-mutated melanoma. The approval is based on an extension in overall survival (OS) from two phase III studies.

As genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions. In the current environment, there's more promise in precision medicine than practical applications in the exam room.

While immunotherapies continue to gain traction across multiple tumor types, including malignancies of the central nervous system, these agents are also associated with unique adverse events.